Idursulfase (Elaprase)

Elaprase (idursulfase) is covered only for the FDA‑approved indication of mucopolysaccharidosis type II (Hunter syndrome) and not for other diagnoses. Coverage requires diagnosis confirmation by deficient iduronate‑2‑sulfatase activity or molecular genetic testing, prescription by or consultation with a geneticist, endocrinologist, metabolic disorder sub‑specialist, or lysosomal storage disorder specialist, dosing ≤0.5 mg/kg IV no more than once weekly, appropriate medical-record documentation, and approvals are issued for up to 12 months.

"Mucopolysaccharidosis Type II (MPS II; Hunter syndrome) — FDA‑approved indication"

Sign up to see full coverage criteria, indications, and limitations.